Allergy, Immunology, and ENT

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

Global meta-analysis identifies eczema, delayed allergen introduction, and early antibiotics as key food allergy risk factors.

The FDA has issued a CRL for Anaphylm sublingual epinephrine, citing human factors and PK study needs; resubmission is anticipated in Q3 2026.

Parents support early peanut introduction but remain confused about timing, purpose, and risks, highlighting the need for clearer pediatric guidance.

Phase 3 data show the Viaskin peanut patch improved desensitization vs placebo in children aged 4 to 7 years, supporting a planned FDA BLA in 2026.

He had no prior history of recurrent ear infections, abscesses, or boils. Can you guess the diagnosis?

Tezepelumab received FDA approval for CRSwNP in patients 12 years and older, supported by strong phase 3 data.

Training tools and EHR prompts boosted pediatricians’ adherence to early peanut introduction guidelines in a new trial.

The clinical report replaces a 2010 report, as food allergy impacts up to 10% of children, with anaphylaxis estimated to occur in 1 in 15 schools per year.

Real-world evidence supports neffy as comparable to epinephrine injection in anaphylaxis care.

Study links early childhood eczema timing to risk of allergies like food allergy, asthma, and rhinitis, with five distinct disease phenotypes identified.

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

The federal agency has assigned a target action date of January 31, 2026, for a decision.

Prescriptions for the epinephrine nasal spray are now available for patients aged 4 years and up who weigh 33 to < 66 lbs.

The study involved 88 pediatric patients, with 12.5% showing positive intradermal test results and 1.1% positive subcutaneous provocation.

In 3 studies evaluating the effects of probiotics on eczema, probiotics groups reported a greater reduction in symptoms than placebo groups, but only when the allergy was IgE mediated.

Allergies can significantly impair daily activities, school performance, and psychological well-being.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April, 2025, issue of Contemporary Pediatrics, with a special focus on pediatric allergy awareness.

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Aquestive Therapeutics reports positive pediatric study results for Anaphylm, supporting its FDA submission for treating severe allergic reactions.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from March 2025.

A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions to small amounts of common food allergens.

In part 2 of this 5-part series, panelists discuss confusion in food allergy diagnosis and the need for better medical education.

In part 1 of this 5-part series, panelists discuss early allergen introduction, oral immunotherapy, and Xolair for food allergy.